ArticleJournal of clinical pathology2002
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Article in Journal of clinical pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 135 citations in OpenAlex.
- Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
- Low E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma.Scientific reports · 2026Article
- Review
- TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities.Virchows Archiv : an international journal of pathology · 2024Article
- Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology.Cancer medicine · 2023Article
- Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.Thoracic cancer · 2022Article
- Mesothelioma.CytoJournal · 2022Review
- Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.Translational lung cancer research · 2020Review
- Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.Turk gogus kalp damar cerrahisi dergisi · 2020Article
- Article
- Malignant Mesothelioma Mimicking Invasive Mammary Carcinoma in a Male Breast.Case reports in oncological medicine · 2015Article
- Pleural mesothelioma: an institutional experience of 66 cases.Korean journal of pathology · 2014Article
- Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer.Medical oncology (Northwood, London, England) · 2013Article
- N-cadherin expression in malignant germ cell tumours of the testis.BMC clinical pathology · 2012Article
- Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.American journal of cancer research · 2012Article
- [Pseudo-mesotheliomatous adenocarcinoma of the lung].Der Pathologe · 2010Article
- Isolated pancreatic metastasis of a malignant pleural mesothelioma.The Kaohsiung journal of medical sciences · 2009Article
- Early photon tomography allows fluorescence detection of lung carcinomas and disease progression in mice in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Carcinoma of unknown primary origin.Gastrointestinal cancer research : GCR · 2007Article
- A genetic mouse model for metastatic lung cancer with gender differences in survival.Oncogene · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe value of immunohistochemical staining in differentiating between malignant mesothelioma and pulmonary adenocarcinoma was re-examined using newly available commercial antibodies, with the aim of increasing the sensitivity and specificity of diagnosis, and simplifying the antibody panel required.
methodsForty one malignant mesotheliomas and 35 lung adenocarcinomas were studied. Commercial antibodies to calretinin, E-cadherin, N-cadherin, surfactant apoprotein A (SP-A), thyroid transcription factor 1 (TTF-1), thrombomodulin, and cytokeratin 5/6 were applied using the streptavidin-biotin-peroxidase complex procedure on formalin fixed, paraffin wax embedded tissue.
resultsE-cadherin was expressed in all adenocarcinomas and in 22% of the mesotheliomas. TTF-1 expression was detected in 69% of the adenocarcinomas and none of the mesotheliomas. Positive staining with polyclonal anticalretinin was detected in 80% of the mesotheliomas and 6% of the adenocarcinomas. N-cadherin was expressed in 78% of mesotheliomas and 26% of adenocarcinomas. Thrombomodulin was expressed in 6% of the adenocarcinomas and in 53% of the mesotheliomas. Cytokeratin 5/6 expression was detected in 6% of the adenocarcinomas and 63% of the mesotheliomas. The results were compared with the standard laboratory panel for mesothelioma diagnosis: anticarcinoembryonic antigen (anti-CEA), LeuM1, BerEP4, and HBME-1.
conclusionOf the antibodies used in this study, E-cadherin was 100% sensitive for pulmonary adenocarcinoma and TTF-1 was 100% specific for pulmonary adenocarcinoma. The application of these two antibodies alone was adequate for the diagnosis of 69% of adenocarcinomas and 78% of mesotheliomas. Where TTF-1 is negative and E-cadherin is positive, a secondary panel of antibodies, including BerEP4 and LeuM1 (CD15) and antibodies directed against CEA, calretinin, cytokeratin 5/6, thrombomodulin, and N-cadherin, is required for differentiation between malignant mesothelioma and pulmonary adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.